Totani Haruhito, Kusumoto Shigeru, Tanaka Yasuhito, Suzuki Nana, Hagiwara Shinya, Kinoshita Shiori, Iio Etsuko, Ito Asahi, Ri Masaki, Ishida Takashi, Komatsu Hirokazu, Iida Shinsuke
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Int J Hematol. 2016 Sep;104(3):384-91. doi: 10.1007/s12185-016-2033-z. Epub 2016 Jun 2.
Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA(+)-M2BP) was developed recently as a predictive marker of progression to liver fibrosis and hepatocellular carcinoma (HCC) in patients seropositive for hepatitis C virus (HCV). We retrospectively analyzed 16 HCV-seropositive patients who received systemic chemotherapy for hematologic malignancies to evaluate the usefulness of WFA(+)-M2BP for predicting HCV-related complications. These were defined as the onset of significant liver damage (LD) with increased HCV RNA levels, leading to interrupted or discontinued chemotherapy or the occurrence of HCC after chemotherapy. Baseline WFA(+)-M2BP levels were determined using preserved serum samples. The median level of WFA(+)-M2BP was 1.59 [cutoff index (C.O.I.) value range 0.38-6.66]. With a median follow-up of 623 days (range 120-2404), LD and HCC were observed in three and two patients, respectively. Detectable HCV RNA and WFA(+)-M2BP ≥2.0 C.O.I. at baseline were identified as risk factors for these HCV-related complications (P = 0.034 and P = 0.005, respectively). The sensitivity, specificity, and positive and negative predictive values of the WFA(+)-M2BP level (cutoff point: 2.0 C.O.I.) for the occurrence of HCV-related complications were 100.0, 81.8, 71.4, and 100.0 %, respectively. WFA(+)-M2BP may be a useful marker for the prediction of HCV-related complications in HCV-seropositive patients following systemic chemotherapy.
紫藤凝集素阳性的人Mac-2结合蛋白（WFA(+)-M2BP）最近被开发为丙型肝炎病毒（HCV）血清学阳性患者进展为肝纤维化和肝细胞癌（HCC）的预测标志物。我们回顾性分析了16例接受血液系统恶性肿瘤全身化疗的HCV血清学阳性患者，以评估WFA(+)-M2BP对预测HCV相关并发症的有效性。这些并发症被定义为出现显著肝损伤（LD）且HCV RNA水平升高，导致化疗中断或停止，或化疗后发生HCC。使用保存的血清样本测定基线WFA(+)-M2BP水平。WFA(+)-M2BP的中位水平为1.59[临界指数（C.O.I.）值范围为0.38 - 6.66]。中位随访623天（范围120 - 2404天），分别有3例和2例患者出现LD和HCC。基线时可检测到的HCV RNA和WFA(+)-M2BP≥2.0 C.O.I.被确定为这些HCV相关并发症的危险因素（分别为P = 0.034和P = 0.005）。WFA(+)-M2BP水平（临界点：2.0 C.O.I.）对HCV相关并发症发生的敏感性、特异性、阳性和阴性预测值分别为100.0%、81.8%、71.4%和100.0%。WFA(+)-M2BP可能是预测全身化疗后HCV血清学阳性患者HCV相关并发症的有用标志物。
